Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin for COVID-19 Prophylaxis (IVERNEX-TUC)
NCT04894721Phase 3Completed
- Sponsor
- Ministerio de Salud
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CHILD-IVITAB in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Ministerio de Salud. Primary endpoint: Number of subjects who were diagnosed with COVID-19 at 2 weeks. Started Jun 2021; status: completed.
02
Drugs
CHILD-IVITAB
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04894721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04894721.